Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review
European Respiratory Review, 2023 Background: The United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk of developing specific neuropsychiatric events in montelukast users remain ...
Chris Wai Hang Lo +8 more
doaj +1 more source
Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions [PDF]
, 2018 Eosinophilic gastrointestinal disorders are a set of conditions with a wide range of clinical manifestations and treatment modalities. The disorders are suspected to result from an abnormal inflammatory response to allergen(s), and individuals may ...
Gupta, Sandeep K., Naramore, Sara
core +1 more source
Recruiting ethnic minority participants to a clinical trial: a qualitative study [PDF]
, 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non ...
Griffiths, C +4 more
core +2 more sources
Skin rash and mild bruising: Is montelukast a safe drug?
Indian Journal of Respiratory Care, 2018 Montelukast is one of the commonly used drugs in asthma patients. It is prescribed along with inhalational corticosteroids. Although a relatively safe drug, there is a probability of occurrence of skin rashes and skin bruising.
Deep Inder +3 more
doaj +1 more source
Phase 2 trial of montelukast for prevention of pain in sickle cell disease. [PDF]
, 2020 Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle cell disease (SCD), levels of CysLTs are increased compared with controls and associated with a higher rate of hospitalization for pain. We tested the hypothesis
Brandow, Amanda +9 more
core
Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s. [PDF]
, 2016 Group 2 innate lymphoid cells (ILC2s) and type 2 helper T cells (Th2 cells) are the primary source of interleukin 5 (IL-5) and IL-13 during type 2 (allergic) inflammation in the lung.
Austen, K Frank +5 more
core +1 more source
Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and non-septic shock. [PDF]
, 2009 The 5-lipoxygenase (5-LO) pathway is responsible for the production of leukotrienes (LTs), inflammatory lipid mediators which play a role in innate immunity. More recently, a pivotal role of LTs in ischemia-reperfusion and shock injury has been suggested.
CUZZOCREA S +2 more
core +1 more source
Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis [PDF]
, 2015 Background: Long-term inhaled corticosteroids (ICS) may reduce growth velocity and final height of children with asthma. We aimed to evaluate the association between ICS use of >12 months and growth.
A Bush +41 more
core +3 more sources
Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019) [PDF]
, 2019 The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on patent activities.
Alcántara, Andrés R. +2 more
core +3 more sources
Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria [PDF]
, 2004 BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU).
DI LORENZO, G. +7 more
core +1 more source